Clinical Revelance
Our cost-effective industry-leading ultra-sensitive NGS liquid biopsy solutions identify tumor mutations across cancer types for even the low-frequency mutant alleles (<0.05%) with high specificity. It provides focused and flexible genomic coverage for a range of intended uses:
- Inform therapy selection
- Dynamically monitor tumor response
- Identify molecular mediators of resistance
- Detect minimal residual disease (MRD) at a variant level
Expert designed ultra-sensitive Plasma-Safe-SeqS panels
- AML-SEQ
- AML-MRD-SEQ
- BC-SEQ
- HNSCC-SEQ
- HPV-SEQ
- RAS-RAF-SEQ